IMDX
STAA
LCTX

BROADWOOD PARTNERS, L.P.

Known title: 10% OwnerCIK: 0001278386

BROADWOOD PARTNERS, L.P.'s purchase track record

How the stock did after each of BROADWOOD PARTNERS, L.P.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
29
of 30 since March 23, 2022
Stock higher 6 months later
59%
3 months: 43%
Median 6-month return
+5.9%
3 months: -5.6%
Beat the S&P 500
52%
median +1.2% vs. index
PurchaseStockAmount3 months6 months
4/24/2026IMDX$1.05M+26.1%pending
4/16/2026IMDX$1.63M+34.2%-12.8%
3/11/2026STAA$12.27M+66.1%+33.8%
2/10/2026IMDX$3.00M-32.8%-39.8%
1/6/2026STAA$9.42M-5.4%+19.1%
11/19/2025STAA$41.06M-33.6%+24.9%
4/3/2025STAA$16.49M+2.6%+57.6%
3/26/2025STAA$2.93M-4.8%+52.4%
3/18/2025STAA$6.00M-9.0%+49.0%
2/27/2025STAA$11.76M+3.6%+54.9%
2/12/2025STAA$6.27M+5.8%+71.2%
2/6/2025IMDX$10.59M+38.5%+28.1%
1/27/2025LCTX$6.00M-25.8%+88.7%
1/14/2025STAA$631K-23.7%-22.1%
12/16/2024STAA$1.95M-26.4%-29.0%
10/2/2024IMDX$3.88M-23.6%-3.3%
5/9/2024STAA$43-5.8%-26.6%
4/11/2024IMDX$7.06M+6.2%+4.5%
2/6/2024LCTX$7.00M+13.5%-18.0%
1/3/2024STAA$6.59M+33.8%+47.6%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 28, 2026

iMDx Amends Chronix Merger Deal Terms. Insight Molecular Diagnostics has amended its merger agreement with Chronix. The change replaces an ongoing 10% royalty on CNI Monitor sales with a one-time 10% payment upon the sale of the CNI Monitor. This structural shift alters the future revenue stream associated with the partnership, moving from recurring income to a single transaction-based payment.

this person other insiders at IMDX

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 14, 2026

STAAR Surgical Names New VP, Faces High Valuation Questions. STAAR Surgical appointed Andrew Pilon as Vice President of Business Development. Recent articles discuss whether the stock is undervalued or risky, noting its high trailing P/E of 283.5. The stock is currently trading near a key support level, with analyst targets ranging from $19.00 to $37.00.

this person other insiders at STAA

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 12, 2026

LCTX Holds Q2 2026 Earnings Conference Call. Lineage Cell Therapeutics held its Q2 2026 earnings conference call, with a transcript released by Benzinga. Management reviewed the quarter's financial results and gave updates on ongoing clinical programs. The discussion provides investors with current insight into the company's performance and future plans. The call occurs while the stock is near its recent support level.

this person other insiders at LCTX

Transaction History

IMDX▲ Buy$0
IMDX▲ Buy$913K
IMDX▲ Buy$137K
IMDX▲ Buy$0
IMDX▲ Buy$982K
IMDX▲ Buy$0
IMDX▲ Buy$158K
IMDX▲ Buy$0
IMDX▲ Buy$143K
IMDX▲ Buy$0
IMDX▲ Buy$352K
IMDX▲ Buy$0
STAA▲ Buy$5.9M
STAA▲ Buy$0
STAA▲ Buy$5.4M
STAA▲ Buy$0
STAA▲ Buy$960K
STAA▲ Buy$0
IMDX▲ Buy$3.0M
IMDX▲ Buy$0
STAA▲ Buy$0
STAA▲ Buy$606K
STAA▲ Buy$0
STAA▲ Buy$71K
STAA▲ Buy$1.5M
STAA▲ Buy$0
STAA▲ Buy$0
STAA▲ Buy$3.9M
STAA▲ Buy$3.4M
STAA▲ Buy$0
STAA▲ Buy$22.2M
STAA▲ Buy$0
STAA▲ Buy$10.7M
STAA▲ Buy$0
STAA▲ Buy$8.2M
STAA▲ Buy$0
STAA▲ Buy$14K
STAA▲ Buy$0
STAA▲ Buy$124K
STAA▲ Buy$0
STAA▲ Buy$185K
STAA▲ Buy$0
STAA▲ Buy$0
STAA▲ Buy$2.5M
STAA▲ Buy$2.0M
STAA▲ Buy$0
STAA▲ Buy$0
STAA▲ Buy$185K
STAA▲ Buy$7.8M
STAA▲ Buy$0
STAA▲ Buy$82K
STAA▲ Buy$0
STAA▲ Buy$3.6M
STAA▲ Buy$0
STAA▲ Buy$554K
STAA▲ Buy$0
STAA▲ Buy$387K
STAA▲ Buy$0
STAA▲ Buy$142K
STAA▲ Buy$0
STAA▲ Buy$63K
STAA▲ Buy$0
STAA▲ Buy$1.8M
STAA▲ Buy$0
STAA▲ Buy$598K
STAA▲ Buy$0
STAA▲ Buy$1.8M
STAA▲ Buy$0
STAA▲ Buy$2.0M
STAA▲ Buy$0
STAA▲ Buy$1.0M
STAA▲ Buy$0
STAA▲ Buy$611K
STAA▲ Buy$0
STAA▲ Buy$298K
STAA▲ Buy$184K
STAA▲ Buy$0
STAA▲ Buy$0
STAA▲ Buy$3.8M
STAA▲ Buy$0
STAA▲ Buy$331K
STAA▲ Buy$0
STAA▲ Buy$2.7M
STAA▲ Buy$0
STAA▲ Buy$32K
STAA▲ Buy$0
STAA▲ Buy$1.9M
STAA▲ Buy$0
STAA▲ Buy$2.5M
STAA▲ Buy$0
STAA▲ Buy$566K
STAA▲ Buy$0
STAA▲ Buy$1.8M
STAA▲ Buy$0
STAA▲ Buy$1.2M
STAA▲ Buy$0
STAA▲ Buy$1.1M
STAA▲ Buy$0
STAA▲ Buy$1.7M
STAA▲ Buy$0
IMDX▲ Buy$1.4M
IMDX▲ Buy$0
IMDX▲ Buy$9.2M
IMDX▲ Buy$0
LCTX▲ Buy$0
LCTX▲ Buy$6.0M
STAA▲ Buy$177K
STAA▲ Buy$0
STAA▲ Buy$454K
STAA▲ Buy$0
STAA▲ Buy$559K
STAA▲ Buy$0
STAA▲ Buy$91K
STAA▲ Buy$0
STAA▲ Buy$1.1M
STAA▲ Buy$0
STAA▲ Buy$181K
STAA▲ Buy$0
IMDX▲ Buy$0
IMDX▲ Buy$3.9M
STAA▲ Buy$43
STAA▲ Buy$0
IMDX▲ Buy$7.1M
IMDX▲ Buy$0
LCTX▲ Buy$0
LCTX▲ Buy$7.0M
STAA▲ Buy$110K
STAA▲ Buy$0
STAA▲ Buy$4.5M
STAA▲ Buy$0
STAA▲ Buy$3K
STAA▲ Buy$0
STAA▲ Buy$1.8M
STAA▲ Buy$0
STAA▲ Buy$190K
STAA▲ Buy$0
STAA▲ Buy$5.6M
STAA▲ Buy$0
STAA▲ Buy$4.9M
STAA▲ Buy$0
STAA▲ Buy$90K
STAA▲ Buy$0
STAA▲ Buy$2.9M
STAA▲ Buy$0
STAA▲ Buy$161K
STAA▲ Buy$0
STAA▲ Buy$17K
STAA▲ Buy$0
STAA▲ Buy$1.1M
STAA▲ Buy$0
STAA▲ Buy$3.9M
STAA▲ Buy$0
STAA▲ Buy$693K
STAA▲ Buy$0
STAA▲ Buy$0
STAA▲ Buy$4.7M
STAA▲ Buy$331K
STAA▲ Buy$0
STAA▲ Buy$5.6M
STAA▲ Buy$0
STAA▲ Buy$19K
STAA▲ Buy$0
STAA▲ Buy$3.1M
STAA▲ Buy$0
STAA▲ Buy$2.0M
STAA▲ Buy$0
STAA▲ Buy$2.8M
STAA▲ Buy$0
STAA▲ Buy$3.7M
STAA▲ Buy$0
STAA▲ Buy$1.2M
STAA▲ Buy$0
STAA▲ Buy$6.1M
STAA▲ Buy$0
STAA▲ Buy$5.4M
STAA▲ Buy$0
STAA▲ Buy$184K
STAA▲ Buy$0
STAA▲ Buy$2.5M
STAA▲ Buy$0
STAA▲ Buy$4.5M
STAA▲ Buy$0
STAA▲ Buy$843K
STAA▲ Buy$0
IMDX▲ Buy$0
IMDX▲ Buy$8.1M
STAA▲ Buy$0
STAA▲ Buy$1.9M
STAA▲ Buy$0
STAA▲ Buy$4.7M
STAA▲ Buy$2.5M
STAA▲ Buy$0
IMDX▲ Buy$8.0M
IMDX▲ Buy$0
LCTX▲ Buy$678K
LCTX▲ Buy$0
LCTX▲ Buy$284K
LCTX▲ Buy$0
LCTX▲ Buy$355K
LCTX▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.